Myosin Inhibitors
Authors:
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyJACC, 2022
- Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2021
- Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2021
- Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathyCirculation, 2021
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic CardiomyopathyJACC, 2020
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyJACC, 2020
- Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic CardiomyopathyJAMA Cardiology, 2016
- Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathyJACC, 2005
- Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic CardiomyopathyNew England Journal of Medicine, 2003